Delving into the Latest Updates on Tislelizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Tirelizumab, Tiselizumab, Tislelizumab (USAN/INN)

+ [8]

Target

PD-1

Action

inhibitors

Mechanism

PD-1 inhibitors(Programmed cell death protein 1 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesDigestive System Disorders+ [10]

Active Indication

Esophageal CarcinomaPD-L1 positive Esophageal Squamous Cell CarcinomaLocally Advanced Gastric Adenocarcinoma+ [119]

Inactive Indication

Advanced biliary tract cancerAdvanced Hepatocellular CarcinomaAdvanced Lung Non-Small Cell Squamous Carcinoma+ [39]

Originator Organization

BeOne Medicines Ltd.

Active Organization

BeOne Medicines Ltd.

AnBogen Therapeutics, Inc.

BeiGene (Shanghai) Co. Ltd.

+ [14]

Inactive Organization

Novartis Pharmaceuticals Corp.

Celgene Corp.

HUTCHMED (China) Ltd.

+ [2]

License Organization

Glenmark Specialty SA

BeOne Medicines Ltd.

Hutchison MediPharma Ltd.

+ [13]

Drug Highest PhaseApproved

First Approval Date

China (26 Dec 2019),

Hodgkin's Lymphoma

RegulationOrphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (China), Special Review Project (China), Orphan Drug (Japan), Priority Review (United States), Priority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 577079733L

Source: *****

Sequence Code 616719194H

Source: *****

This is a Phase 2, single-arm, multicenter study, evaluating the anti-tumor efficacy of tumor-infiltrating lymphocyte (TIL) directed tislelizumab monotherapy (also known as BGB-A317) for refractory solid tumors in approximately 72 patients with centrally confirmed T cell inflamed GEP score ≥ 0.857, who have not been previously exposed to immunotherapy.
All patients must provide a tumor specimen for T cell inflamed GEP assessment. Archived tissue slide collected within 2 years from the first dose of study drug must be provided.
This study will include a Screening Period, a Treatment Period, and a Follow-Up Period. All patients will complete up to 28 days of screening. During the Treatment Period, patients will receive tislelizumab 200 mg fixed dose once every 3 weeks by intravenous (IV) administration until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
After treatment discontinuation, patients will be follow-up for disease progression and survival status until death, withdrawal of consent, or study closure, whichever occurs first.
The end of study will be the timepoint when the final data for the study were collected. Additionally, the Investigator Sponsor has the right to terminate this study at any time.

Start Date01 Aug 2026

Sponsor / Collaborator

Samsung Medical Center

NCT07472933

/ Not yet recruitingPhase 2IIT

An Exploratory Study of Vedotin-tislelizumab Combined With Toripalimab in EGFR-positive Refractory Advanced Biliary Tract Malignancies

This study aims to observe the efficacy and safety of the combination of vebecotototo monoclonal antibody and putli monoclonal antibody in the treatment of EGFR-positive refractory biliary malignant tumors.

Start Date01 Aug 2026

Sponsor / Collaborator

West China Hospital

100 Clinical Results associated with Tislelizumab

Login to view more data

100 Translational Medicine associated with Tislelizumab

Login to view more data

100 Patents (Medical) associated with Tislelizumab

Login to view more data

782

Literatures (Medical) associated with Tislelizumab

01 Aug 2026·MEDICINA CLINICA

A case of thrombotic microangiopathy during tislelizumab therapy for lung cancer

Letter

Author: Zou, Yumeng ; Zhang, Nannan

15 Jul 2026·INTERNATIONAL JOURNAL OF CANCER

Efficacy and safety of bronchial arterial infusion chemotherapy combined with transarterial chemoembolization and systemic therapy in hepatocellular carcinoma patients with lung metastases

Article

Author: Yuqi Jiang ; Changyu Li ; Juncheng Wan ; Yongjie Zhou ; Chaoqiao Jin ; Xudong Qu ; Caihong Yu

Abstract:

This study evaluated the efficacy and safety of bronchial arterial infusion (BAI) chemotherapy combined with transarterial chemoembolization (TACE) plus systemic therapy in hepatocellular carcinoma (HCC) patients with lung metastases. This study retrospectively analyzed 54 HCC patients with lung metastases who underwent TACE combined with systemic therapy and/or BAI chemotherapy, at initial diagnosis from January 2018 to June 2023. Systemic therapy included targeted agents (apatinib, lenvatinib, and regorafenib, or bevacizumab) and programmed cell death protein 1 (PD‐1) inhibitors (sintilimab, camrelizumab, and tislelizumab). During follow‐up, treatment‐related adverse events were recorded. Progression‐free survival (PFS) was assessed separately for lung metastases and intrahepatic lesions, along with overall survival (OS). Fifty‐four eligible patients with HCC were enrolled, including 32 in the BAI plus TACE and systemic therapy group (BTS group) and 22 in the TACE plus systemic therapy group (TS group). At 3 months post‐treatment, the BTS group showed significantly higher objective response rate of lung metastatic lesions (50.0% vs. 22.7%, p = .043) and disease control rate (DCR) (93.7% vs. 68.2%, p = .013) than the TS group. By study end, DCR remained higher in the BTS group (84.4% vs. 54.5%, p = .016). Median PFS of lung metastatic lesions was 7.1 versus 3.3 months ( p = .004), and median OS was 13.9 versus 7.6 months ( p = .009), both favoring the BTS group. The combination of BAI, TACE, and systemic therapy achieved favorable therapeutic outcomes and acceptable safety in patients with HCC with lung metastases.

15 Jun 2026·CLINICAL CANCER RESEARCH

The Efficacy and Safety of Tislelizumab plus Anlotinib as First-line Treatment in Advanced Pulmonary Sarcomatoid Carcinoma: A Single-Arm Phase II Trial

Article

Author: Zhang, Xiaoqiang ; Cai, Jing ; Zeng, Zhimin ; Huang, Wenqian ; Zheng, Yue’e ; Liu, Chenyi ; Zeng, Fujuan ; Huang, Long ; Chen, Ziye ; Liu, Anwen ; Xiong, Le

Abstract:

Purpose::

Pulmonary sarcomatoid carcinoma (PSC) is a highly aggressive and poorly differentiated subtype of non–small cell lung cancer (NSCLC) associated with a poor prognosis. We conducted a prospective, single-arm, phase II trial to evaluate the efficacy and safety of tislelizumab in combination with anlotinib as first-line therapy in patients with advanced PSC.

Patients and Methods::

Eligible patients with advanced PSC without EGFR or ALK mutations received tislelizumab plus anlotinib as first-line treatment until disease progression or unacceptable toxicities. The primary endpoint was the objective response rate (ORR) assessed per RECIST version 1.1. Secondary endpoints included the disease control rate (DCR), duration of response, progression-free survival (PFS), overall survival (OS), and safety.

Results::

Between August 2021 and June 2025, a total of 29 patients were enrolled, with a median age of 71 years (range: 39–79). Two patients (6.90%) achieved a complete response, and 14 (48.28%) achieved a partial response, yielding an ORR of 55.17% [95% confidence interval (CI), 35.69%–73.55%]. The DCR was 96.55% (95% CI, 82.24%–99.91%). After a median follow-up duration of 16.73 months, the median PFS was 9.40 months (95% CI, 3.67–13.30 months), and the median OS was 14.37 months (95% CI, 9.03–17.50 months). The most common treatment-related adverse events (TRAE) were hyperuricemia and maculopapular rash. Grade 3 to 4 TRAEs occurred in eight patients (27.59%), with no treatment-related deaths reported.

Conclusions::

The combination of tislelizumab and anlotinib demonstrated promising antitumor activity with a manageable safety profile as first-line therapy in patients with advanced PSC.

616

News (Medical) associated with Tislelizumab

15 Jul 2026

·www.prnewswire.com

GEM and Senhwa Biosciences have formally executed a Share Purchase Agreement for up to NT$500 million

TAIPEI and SAN DIEGO, July 14, 2026 /PRNewswire/ -- GEM Global Yield LLC SCS ("GEM") has executed a Share Purchase Agreement (the "SPA") with the existing shareholders of Taiwan-listed Senhwa Biosciences Inc. (TPEx: 6492), under which GEM has committed up to NT$500 million (approximately US$15.5 million) to purchase shares in the Company over the next 3-5 years. Purchases under the SPA may occur from time to time at the election of certain shareholders, subject to the terms and conditions of the SPA. During the lifetime of the SPA, GEM will not, directly or indirectly, effect any short sale of Senhwa's shares. Taiwan's biotechnology industry continues to attract increasing international attention through innovative oncology research, expanding global clinical collaborations and the adoption of artificial intelligence to accelerate drug discovery and clinical development. Under the framework of the SPA, the equity commitment from GEM provides additional financial flexibility and is expected to support continued investment in Senhwa's clinical pipeline, potential in-licensing opportunities, and AI-enabled pipeline prioritization and expansion. The company's lead assets are CX-5461 (pidnarulex) and CX-4945 (silmitasertib), two investigational oncology therapies being studied across multiple cancer indications. Senhwa has established research and development collaborations with organizations including the U.S. National Cancer Institute (NCI), BeOne Medicines, and CellType, a Y Combinator-backed artificial intelligence company whose platform incorporates technology developed with Google DeepMind. "We are very pleased that a prominent international investment group like GEM recognizes Senhwa's long-term potential and has chosen to provide access to significant capital to Senhwa over the next few years," said Dr. Pin-Yen Huang, Acting Chief Executive Officer of Senhwa Biosciences. "GEM's validation strengthens our global market positioning as we continue to advance our oncology pipeline, expand strategic international collaborations, and bring innovative therapies to patients around the world." CX-5461 is currently involved in studies sponsored by the NCI and Senhwa expects to initiate a clinical study combining the drug with BeOne Medicines' PD-1 antibody, tislelizumab. CX-4945 is being investigated across several oncology indications, including cholangiocarcinoma, CNS tumors and pediatric cancers. In addition, preclinical studies are evaluating both compounds as potential combination partners for RAS-targeted therapies, although their clinical utility in this setting has not yet been established. From a regulatory standpoint, both candidates have secured orphan drug and rare pediatric disease designations from health authorities. For biotech investors, the pediatric designation is a key metric, as it preserves the company's eligibility to receive a marketable Priority Review Voucher (PRV) should the drugs eventually secure regulatory approval. About GEM GEM Global Yield LLC SCS ("GEM") is a $3.4 billion private equity and alternative investment group with offices in Paris, New York, and Nassau (Bahamas). GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 590 transactions in 70 countries. Its family of funds and investment vehicles provide GEM and its partners with exposure to small-mid cap management buyouts, private investments in public equities, and select venture investments. About Senhwa Biosciences Senhwa Biosciences Inc. is a Taiwan-based biotechnology company developing novel oncology therapeutics for cancers with significant unmet medical needs. Its pipeline includes CX-5461 and CX-4945, which are being evaluated across solid tumors and hematologic malignancy indications through international clinical and research collaborations. Forward-Looking Statements This release contains forward-looking statements regarding, among other things, anticipated financing, clinical development plans, regulatory milestones, strategic collaborations and the potential development of investigational drug candidates. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including risks related to clinical development, regulatory review, financing, commercialization and market conditions. Nothing contained herein should be construed as a guarantee of future clinical, regulatory or commercial outcomes. SOURCE Senhwa Biosciences, Inc 21% more press release views with Request a Demo

Orphan DrugLicense out/in

10 Jul 2026

·www.fiercepharma.com

FDA rejects Hengrui, Elevar’s PD-1 liver cancer combo for a 3rd time

The third time is not the charm for Hengrui Pharma and Elevar Therapeutics’ star-crossed combination of camrelizumab and rivoceranib at the FDA. U.S. regulators have declined to approve the anti-PD-1/VEGFR combo for a third time as a first-line treatment for liver cancer, Hengrui and Elevar’s parent company, HLB Group, said in separate announcements Friday. The problem, again, is manufacturing. Only this time, the complete response letter (CRL) stemmed from deficiencies the FDA had identified in April at the plant producing rivoceranib, also known as apatinib, unlike the previous two rejections , which centered on Hengrui’s camrelizumab facility, according to the Chinese pharma. The rivoceranib manufacturer had passed an inspection by EU authorities in 2025, it noted. Still, three CRLs do not necessarily mean three strikes and you're out for Hengrui and Elevar. “The company has thoroughly evaluated the regulator’s feedback and is taking steps to implement appropriate corrective measures,” Hengrui said in a securities filing (Chinese, PDF) in Shanghai. “The company will actively communicate with the FDA and our partner, Elevar Therapeutics, to establish the next resubmission plan.” Elevar “intends to promptly address the aforementioned deficiencies and resubmit the application for FDA approval,” HLB said in its own securities filing to the Korea Exchange. As Elevar noted, a re-inspection by the FDA may be required to determine that the facility meets CGMP compliance requirements. More than two years have passed since the FDA first snubbed the camrelizumab-rivoceranib regimen in May 2024. The second CRL arrived in March 2025. And Elevar refiled the newest application on Jan. 23, 2026. The latest CRL does not raise any issues with clinical data, Hengrui said. For this application, the two companies provided updated final analysis from the phase 3 Cares-310 trial, which showed a 36% death risk reduction for camrelizumab and rivoceranib versus Bayer’s Nexavar in first-line unresectable hepatocellular carcinoma. Chinese companies have long viewed follow-on PD-1 inhibitors as a viable entry point into the highly lucrative U.S. innovative drug market. However, these candidates have faced a string of regulatory and operational setbacks along the way. In a high-profile decision that triggered ripple effects across the industry, the FDA in 2022 refused to approve Innovent Biologics’ then Eli Lilly-partnered Tyvyt, citing predominantly China-only data as a problem. Thanks to that policy, Novartis abandoned its U.S. submission plan in first-line non-small cell lung cancer for Tevimbra before returning the asset to BeOne Medicines, then known as BeiGene. The same fate met CStone Pharmaceuticals’ PD-L1 inhibitor sugemalimab and its partnership with EQRx, which was absorbed into Revolution Medicines in 2023. Besides Hengrui, Fosun Pharma is also angling its China-approved PD-1 inhibitor, serplulimab, for an initial FDA approval in extensive-stage small cell lung cancer. Despite the positive phase 3 Astrum-005 trial, which showed the drug beat placebo, both added to chemotherapy, Fosun had to conduct a U.S. bridging study that compared serplulimab to Roche’s Tecentriq. With that study recently complete, Fosun is in discussions with the FDA about a potential filing this year.

Clinical ResultPhase 3Drug ApprovalNDAADC

17 Jun 2026

·www.biospace.com

Jazz strikes new chord with AbCellera in T cell engager pact that could top $2.4B

Getty Images/ seamartini Jazz Pharmaceuticals is diversifying its oncology strategy, orchestrating a new antibody deal with AbCellera that offers $56 million upfront, plus $792 million in biobucks for each of the three initial programs. Jazz Pharmaceuticals is banding together with AbCellera, paying $56 million cash and offering up to some $2.46 billion in total to develop next-generation T cell engagers for hard-to-treat cancers. The collaboration features AbCellera’s multispecific T cell engager (TCE) platform, science that will be fine-tuned in hopes of creating candidates for multiple gastrointestinal (GI) cancers and other solid tumors for which current treatments fall flat. AbCellera will perform discovery and early-stage research for two initial programs, with plans to start a third discovery program in the next year, according to a Wednesday release . For each program, Jazz can opt in for a fee that would grant the biopharma exclusive rights to the candidate. Should Jazz exercise its option, AbCellera could be in line to receive up to $792 million in milestone payments per program, plus tiered royalties. For the work on the first two programs, Canada-based AbCellera will receive $56 million upfront. The biotech will get another $28 million when work on the third program begins. Under the terms of the deal, the partners can also tack on two additional programs, though potential payments for these were not disclosed. “This research collaboration with AbCellera directly aligns with Jazz’s rare disease strategy, expanding our focus on GI cancers and building on our existing expertise in oncology,” Jazz Chief Scientific Officer Josh Allen said in the release. “We look forward to collaborating with AbCellera to progress potential best-in-class TCE multispecific antibodies for GI cancers and other solid tumors into clinical development and to develop meaningful innovation for patients.” For Truist analysts, the move underscores Jazz’s growing focus on GI cancers. The expansion builds off Ziihera, a bispecific HER2-directed antibody that has secured priority review for a label expansion into first-line HER2+ gastroesophageal adenocarcinoma, with an FDA decision expected on or by Aug. 25. Stomach cancer Jazz’s Ziihera Shows ‘Practice-Changing’ Efficacy in Stomach Cancer Jazz’s Ziihera and BeOne’s Tevimbra plus chemotherapy led to what Truist Securities dubbed one of the strongest overall survival signals ever reported in a type of gastroesophageal cancer. January 7, 2026 · 2 min read · Tristan Manalac Read more “We view continued external BD as reinforcing the balanced-portfolio thesis as JAZZ’s onco lean-in and diversification effort has been lively,” Truist wrote in a Wednesday morning note. “While this deal brings additional oncology flavor to the JAZZ platform, we continue to anticipate recurring BD activity in rare disease spaces,” the analysts added. The move also comes directly after Jazz’s alkylating drug Zepzelca failed to improve overall survival for patients with relapsed metastatic small cell lung cancer in a Phase 3 trial last week. The study brings a second line expansion into question, Truist analysts said in a June 12 note, adding, however, that they see the first-line indication as the primary growth driver. Now Jazz will have access to AbCellera’s platform, which includes proprietary panels of CD3-binding antibodies and rapid testing systems to help design multispecific drugs. “Building on years of experience in TCEs, we are pleased to partner with Jazz Pharmaceuticals to leverage AbCellera’s differentiated TCE platform to bring forward novel cancer treatments for GI cancers and other solid tumors,” AbCellera founder and CEO Carl Hansen said in a prepared statement. AbCellera has also teamed up with AbbVie, last year expanding an existing deal to include TCEs for oncology.

Phase 3Priority Review

100 Deals associated with Tislelizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11487	Tislelizumab	L01XC	DB14922

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Esophageal Carcinoma	Japan	BeOne Medicines Ltd.	27 Mar 2025
PD-L1 positive Esophageal Squamous Cell Carcinoma	United States	BeOne Medicines USA, Inc.	03 Mar 2025
Locally Advanced Gastric Adenocarcinoma	European Union	BeOne Medicines Ltd.	19 Dec 2024
Locally Advanced Gastric Adenocarcinoma	Iceland	BeOne Medicines Ltd.	19 Dec 2024
Locally Advanced Gastric Adenocarcinoma	Liechtenstein	BeOne Medicines Ltd.	19 Dec 2024
Locally Advanced Gastric Adenocarcinoma	Norway	BeOne Medicines Ltd.	19 Dec 2024
Locally Advanced Gastroesophageal Junction Adenocarcinoma	European Union	BeOne Medicines Ltd.	19 Dec 2024
Locally Advanced Gastroesophageal Junction Adenocarcinoma	Iceland	BeOne Medicines Ltd.	19 Dec 2024
Locally Advanced Gastroesophageal Junction Adenocarcinoma	Liechtenstein	BeOne Medicines Ltd.	19 Dec 2024
Locally Advanced Gastroesophageal Junction Adenocarcinoma	Norway	BeOne Medicines Ltd.	19 Dec 2024
Metastatic gastric adenocarcinoma	European Union	BeOne Medicines Ltd.	19 Dec 2024
Metastatic gastric adenocarcinoma	Iceland	BeOne Medicines Ltd.	19 Dec 2024
Metastatic gastric adenocarcinoma	Liechtenstein	BeOne Medicines Ltd.	19 Dec 2024
Metastatic gastric adenocarcinoma	Norway	BeOne Medicines Ltd.	19 Dec 2024
Metastatic Gastroesophageal Junction Adenocarcinoma	European Union	BeOne Medicines Ltd.	19 Dec 2024
Metastatic Gastroesophageal Junction Adenocarcinoma	Iceland	BeOne Medicines Ltd.	19 Dec 2024
Metastatic Gastroesophageal Junction Adenocarcinoma	Liechtenstein	BeOne Medicines Ltd.	19 Dec 2024
Metastatic Gastroesophageal Junction Adenocarcinoma	Norway	BeOne Medicines Ltd.	19 Dec 2024
Resectable Lung Non-Small Cell Carcinoma	China	BeiGene Guangzhou Biologics Manufacturing Co. Ltd.	16 Oct 2024
Extensive stage Small Cell Lung Cancer	China	BeiGene Guangzhou Biologics Manufacturing Co. Ltd.	25 Jun 2024

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HER2 Positive Adenocarcinoma of Esophagus	NDA/BLA	United States	BeOne Medicines Ltd.	29 Apr 2026
HER2 positive Gastrooesophageal junction cancer	NDA/BLA	United States	BeOne Medicines Ltd.	29 Apr 2026
HER2-positive gastric cancer	NDA/BLA	United States	BeOne Medicines Ltd.	29 Apr 2026
HER2 Positive Stomach Adenocarcinoma	NDA/BLA	China	Boehringer Ingelheim Biopharmaceuticals (China) Ltd.	14 Apr 2026
HER2 Positive Stomach Adenocarcinoma	NDA/BLA	China	BeiGene Guangzhou Biologics Manufacturing Co. Ltd.	14 Apr 2026
stomach adenocarcinoma	NDA/BLA	European Union	BeOne Medicines Ireland Ltd.	17 Oct 2024
Squamous Cell Carcinoma	NDA/BLA	China	BeOne Medicines Ltd.	06 Sep 2018
Advanced Gastroesophageal Junction Adenocarcinoma	Phase 3	China	RemeGen Co., Ltd.	01 Jan 2026
HER2-expressing Gastroesophageal Junction Adenocarcinoma	Phase 3	China	RemeGen Co., Ltd.	01 Jan 2026
Colorectal Cancer	Phase 3	France	BeOne Medicines Ltd.	16 Apr 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05909904 (CTgov)	Phase 2	Squamous cell carcinoma of head and neck metastatic	160	Tislelizumab (Tislelizumab)	gjtereqktx = iefmuisrve mzphvkngmj (kemlxejfqc, rbpfjwqrgd - erpdmpqccj) View more	-	14 Jul 2026
NCT05909904 (CTgov)	Phase 2	Squamous cell carcinoma of head and neck metastatic	160	Tislelizumab+BGB-A425 (Tislelizumab + Surzebiclimab)	gjtereqktx = ntdaybsuew mzphvkngmj (kemlxejfqc, wmfjgqbrfc - lqqmlwbikp) View more	-	14 Jul 2026
NCT05609370 (CTgov)	Phase 1/2	Metastatic Microsatellite Stable Colorectal Carcinoma \| Metastatic Colorectal Carcinoma	113	Tislelizumab+Bevacizumab+Alcestobart+Fluoropyrimidine (FP) (Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine)	filtihcqhd = mftihstblu xinbpvlzxb (ofhmudgvsl, qsxarwxrrv - spsonirmks) View more	-	30 Jun 2026
NCT05609370 (CTgov)	Phase 1/2		113	Tislelizumab+Bevacizumab+Alcestobart+Fluoropyrimidine (FP) (Phase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine)	filtihcqhd = zytuegmpel xinbpvlzxb (ofhmudgvsl, ammeuotfnj - zkzrlwbclf) View more	-	30 Jun 2026
Pubmed \| Clin Cancer Res	Phase 2	Pulmonary sarcomatoid carcinoma First line	29	Tislelizumab plus Anlotinib	bvfykluuuf(wrepunbbjm) = omdqymtolj jfhpllmqyh (qofdwibumv, 35.69 - 73.55) View more	Positive	15 Jun 2026
NCT05520619 (EC-CRT-002, Pubmed \| J Clin Oncol)	Phase 2	Locally Advanced Esophageal Squamous Cell Carcinoma	114	Tislelizumab + Induction Chemotherapy + Concurrent Chemoradiotherapy	keztbdtisc(myembsvqql): HR = 0.54 (95.0% CI, 0.32 - 0.94) View more	Positive	01 Jun 2026
NCT05520619 (EC-CRT-002, Pubmed \| J Clin Oncol)	Phase 2	Locally Advanced Esophageal Squamous Cell Carcinoma	114	Tislelizumab + Induction Chemotherapy + Concurrent Chemoradiotherapy		Positive	01 Jun 2026
NCT03594747 (RATIONALE-307, Pubmed \| Oncol Ther)	Phase 3	Squamous non-small cell lung cancer First line	665	Tislelizumab plus paclitaxel/carboplatin	prwagxmoau(rmswanqubo) = qtvqyxcrga lypebxkaik (lodjzznfjq, 6.7 - 9.9) View more	Positive	01 Jun 2026
NCT03594747 (RATIONALE-307, Pubmed \| Oncol Ther)	Phase 3	Squamous non-small cell lung cancer First line	665	Tislelizumab plus nab-paclitaxel/carboplatin	prwagxmoau(rmswanqubo) = mgwnllivdr lypebxkaik (lodjzznfjq, 7.4 - 10.1) View more	Positive	01 Jun 2026
NCT05542342 (GEM-2101 \| SITISVEAL, CTgov)	Phase 2	Uveal Melanoma \| Liver metastases \| Metastatic melanoma	16	Tislelizumab+Sitravatinib	duulucznen = ahegxtbsmd yrynoosbhc (ahtjqvcrah, sgrufalhuq - ouqfikfmqw) View more	-	01 Jun 2026
ASCO2026	Not Applicable	Squamous Cell Carcinoma of Head and Neck Neoadjuvant	101	tislelizumab+albumin-bound paclitaxel+ cisplatin	fmiipdoesc(rslrkqtbju) = ninigyznyb tzwjgewfiw (rqdzarxbky ) View more	Positive	29 May 2026
NCT05253118 (SPECTRUM, ASCO2026)	Phase 2	Diffuse Large B-Cell Lymphoma	29	TislelizumabPemetrexedab + TislelizumabPemetrexed	bckcotnfze(hbrikqtglt) = iomdpnbmkf wnqkjyvajf (vdzvkosgtv ) View more	Positive	29 May 2026
ChiCTR2400084683 (ASCO2026)	Phase 2	Advanced Nasopharyngeal Carcinoma Adjuvant	30	Tislelizumab + gemcitabine + cisplatin (induction) → cisplatin (concurrent) → Tislelizumab + capecitabine (adjuvant) (high-risk locoregionally advanced nasopharyngeal carcinoma)	aachateeef(zqblqyefpa) = ngezondwgy oyxwcjbnuj (nanesoyczz ) View more	Positive	29 May 2026
NCT05515315 (ASCO2026)	Phase 2	Locally Advanced Esophageal Squamous Cell Carcinoma Maintenance \| Induction	77	Induction chemoimmunotherapy followed by concurrent chemoradiotherapy and sequential immune maintenance therapy	vvuiblvtgv(gteqbonptl) = hxysxilaeq hhtcuxxghl (xifpuoddtn, 12.0 - 36.0) View more	Positive	29 May 2026

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Tislelizumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation